AACR-NCI-EORTC 2017: Combination Therapy With New Antibody-Drug Conjugate in Mesothelioma or Lung Cancer
In patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non–small cell lung cancer (NSCLC), combination treatment of a new antibody-drug conjugate (anetumab ravtansine) with standard dosing of pemetrexed/cisplatin showed early signs of clinical efficacy, with future study warranted. At a dosage of 6.5 mg/kg for anetumab ravtansine, there seemed to be no evidence of pharmacokinetic interaction and a manageable toxicity profile. These results were presented by Raffit Hassan, MD, of the National Cancer Institute, and colleagues at the 2017 American Association for Cancer Research–National Cancer Institute–European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics (Abstract A065) in Philadelphia.
A total of 17 patients received 2 or more cycles of treatment including 7 patients with pleural mesothelioma, 9 with peritoneal mesothelioma, and 1 with NSCLC. The treatment consisted of a 1-hour intravenous (IV) infusion on day 1 of every 21-day treatment cycle of anetumab ravtansine along with IV infusions of pemetrexed at 500 mg/m2 and cisplatin at 75 mg/m2.
Most adverse effects to the treatment were G1 and G2 eye toxicities. Of 13 patients treated with a 6.5-mg/kg dose of anetumab ravtansine in combination with chemotherapy, the overall response rate was 46%.